Poly Medicure Q4 consolidated profit drops 29% on acquisition costs
The medical device maker reported a sharp decline in quarterly consolidated profit, though the results align with previously disclosed guidance revisions.
What's new
- Consolidated Q4 net profit fell 29% year-on-year.
- Standalone Q4 net profit dropped 7% year-on-year.
- The board recommended a dividend and reappointed the company's auditors.
Why this matters
The profit decline reflects acquisition-related costs that were already baked into the company's outlook. Because management previously lowered revenue baselines for PendraCare and reduced renal growth targets, these results confirm existing trends rather than introducing new volatility.
What we're watching
- Whether acquisition-related costs stabilize in the coming quarters.
- Actual performance against the revised renal growth targets.
- Integration progress of recent acquisitions.
The full read
Poly Medicure closed the fiscal year with a 29% year-on-year drop in consolidated Q4 net profit. The standalone business fared better, posting a 7% decline for the same period. These results are largely a reflection of acquisition-related costs that the market had already priced in.
No surprises here.
Management previously lowered revenue expectations for PendraCare and trimmed renal growth targets, meaning today's disclosure confirms a trajectory already established in earlier communications. With the guidance revisions already behind us, the focus shifts to whether the company can stabilize margins as it integrates its recent acquisitions while maintaining its market share in a competitive medical device landscape.
Questions answered
- Why did consolidated profit fall by 29%?
- The decline is attributed to acquisition-related costs incurred during the period. These expenses were anticipated following the company's prior disclosures.
- How did the standalone results compare to the consolidated ones?
- Standalone Q4 net profit saw a more modest decline of 7% year-on-year, compared to the 29% drop in consolidated profit.
- Did this filing introduce new guidance changes?
- No. The filing reaffirms previously known trends, and the company's prior guidance revisions regarding PendraCare and renal growth targets remain the primary benchmarks.
- What corporate actions did the board take?
- The board approved the audited financial results for the year ended March 31, 2026, recommended a dividend, and reappointed the company's auditors.